Ǧ ʹ Key points • Expansion of circulating monocytic myeloid derived suppressor cells (MDSCs) correlates with clinical outcomes in patients with DLBCL.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, accounting for around 40% of new cases. Although DLBCL is recognized as a single entity by the World Health Organization, several subgroups with different outcomes have been described. 1 Despite introduction of immunotherapy, treatment failure is observed in around 40% of DLBCL, emphasizing the need for prognostic biomarkers. 2 The International Prognostic Index (IPI), with variants, still considered the standard prognostic factor for DLBCL, stratifies patients at diagnosis. However this score does not take into account biological differences among subgroups. [3] [4] [5] Additional prognostic factors, evaluated at the time of diagnosis, include various cytokines (soluble PD-L1, 6 CxCL10, 7 IL-10) 7 , tumor characteristics (cell of origin, 8 LMO2, 9 MYC-, BCL2-and BCL6-rearrangements) 10 and components from the tumor microenvironment (CD3 pos , CD4 pos and Foxp3 tumor infiltrating T cells, 11, 12 CD68 pos myeloid cells). 2, 13, 14 Recently, an increase in circulating neutrophil 15 or monocyte 16, 17 counts, combined with a decrease in lymphocyte count (so-called LMR: lymphocyte to monocyte ratio and NLR: neutrophil to lymphocyte ratio) have been proposed as independent prognostic markers in the Rituximab era.
Specific granulocyte and monocyte subsets have demonstrated their immunosuppressive functions in cancers as well as in inflammatory diseases and are recognized as myeloid derived suppressor cells (MDSCs). 18, 19 These cells are immature, arise from the myeloid lineage, and are defined by their immunosuppressive function. Human MDSCs, a heterogeneous population with a lack of specific markers, belong to 2 major types: granulocytic (G-MDSC, Lin neg HLA-Ǧ Ͷ have been associated with MDSCs. 19 Interestingly, these markers are likely regulated through various stimuli depending on the tumor type. 20 MDSC induction and expansion are mediated by a combination of soluble factors (including VEGF, GM-CSF, M-CSF, S100A8/A9, IL-4, IL-6, IL-10) produced by tumor and/or surrounding cells such as stromal cells, T cells or macrophages. 19 These factors essentially trigger activation of the STAT3, STAT6 and STAT1 family, leading to the expression of genes involved in the blockade of the myeloid differentiation or in immune regulation. These multiple suppressive mechanisms converge to impair effector T cell and NK cell functions and also contribute to macrophage polarization towards a M2
anti-inflammatory phenotype. In human, various mechanisms have been described including i) regulatory T cell (T reg ) expansion, ii) depletion in amino acids essential for T-cell metabolism by expression of arginase 1 (ARG1) or indoleamine 2,3dioxygenase (IDO), iii) production of reactive oxygen species (ROS) by expression of NADPH oxidase (NOX2), and iv) IL-10, TGFβ release and PD-L1 expression. 20, 21 In most solid cancers studied (melanoma, renal, lung or prostate cancer, hepatocellular carcinoma), although both G-and M-MDSCs were increased, a predominance of G-MDSCs was mostly detected. 22, 23 However, by using a model which allowed separate study of G-and M-MDSCs in tumor-bearing mice,
Haverkamp et al. demonstrated that M-MDSC was the most suppressive subset and that loss of G-MDSCs did not alter tumor incidence. 24 In lymphoid malignancies, an enrichment in circulating MDSCs has been described in myeloma, 25 T-cell lymphoma, 26 chronic lymphocytic leukemia (CLL) 27 and DLBCL. 28, 29 In DLBCL, G-MDSCs have never been studied, and only arginase 1 expression has been evaluated as a mechanism of M-MDSC-mediated immunosuppression. 28, 29 Here, we hypothesized that the increase in neutrophils and monocytes in peripheral blood of 
Fluorescent flow cytometry analysis
Blood samples were collected on heparin tubes. Plasma specimens were stored at −80°C until use. White blood cell (WBC) differential was performed using Cytodiff TM panel (CD36, CD2, CD294, CD19, CD16, CD45, Beckman Coulter, Brea, CA, USA) on 50µL of blood as previously described. 31 Flow cytometry analysis of M-MDSCs, G-MDSCs and dendritic cells were performed on whole blood (300µL/tube) with the antibody panels described in Supplemental cells/L), percentages or mean florescence intensity (MFI).
Cytokines and enzymes assessment
Concentrations of IL-10 (eBioscience, San Diego, CA, USA), TGF-β1 (R&D Systems, Minneapolis, MN, USA), S100A8/9, S100A12 and Arginase I (Hycult Biotech, Ude,
The Netherlands) in the plasma or culture supernatants were measured by enzymelinked immunosorbent assay (ELISA), according to manufacturer's recommendations. Finally, arginase I and IDO activities were evaluated by highperformance liquid chromatography (HPLC) analysis 32 as the ornithine to arginine and tryptophan to kynurenine ratio, respectively.
T-cell proliferation assay
Fresh PBMC from DLBCL or HD samples were separated into two fractions. The first fraction was positively depleted for residual erythrocytes using glycophorin A beads penicillin-streptomycin (Gibco, Saint Aubin, France). Then, cells were stimulated with soluble anti-CD3 (0.6μ/mL, Sanquin, Amsterdam, The Netherlands) and anti-CD28 (0.6μ/mL, Sanquin) and cultured at 37°C in 5% CO2 and 100% humidity for 4 days.
For some experiments, CD3 pos T cells were purified using magnetic beads (CD3 microbeads, Miltenyi Biotec), labeled with CFSE, and cocultured with autologous CD14 pos HLA-DR low or CD14 pos HLA-DR high sorted cells (FACS ARIA III; BD Biosciences) with a ratio of 2:1 in the presence of anti-CD3/anti-CD28 stimulation.
CFSE dilution was assessed by flow cytometry and analyzed with ModFit LT
software (Verity Software House, Topsham, ME, USA). Results were expressed by the proliferation index (PI).
T-cell proliferation assay with inhibitors
Cryopreserved PBMC from DLBCL patients depleted for residual erythrocytes were CFSE labeled and then platted in triplicate at 10 6 cells/mL in RPMI 1640 medium enriched with 10% of human serum AB, 1% penicillin-streptomycin in 96-well roundbottom plates and incubated at 37°C for 30 minutes with or without different neutralizing antibodies: anti-IL-10 (10μg/mL, R&D systems); anti-S100A12 (10μg/mL, Acris, San Diego, CA, USA) and anti-PD1 (20μg/mL, clone 3.1 given by Professor Daniel Olive) 33 or with chemical analogs: L-1MT (1mM, Sigma-Aldrich, Diegem, Belgium) 34 and nor-NOHA (20mM, Enzo Life Sciences, Antwerpen, Belgium). At the concentration employed, nor-NOHA inhibited >80% of the arginase 1 activity on a positive control (data not shown). Thereafter, cells were stimulated with soluble anti-CD3 and anti-CD28 and incubated at 37°C in 5% CO2 and 100% humidity for 4 days.
CFSE dilution was assessed by flow cytometry and analyzed with ModFit LT
For personal use only. on July 8, 2016. by guest www.bloodjournal.org From Ǧ ͳ ͳ software. Results were expressed as the percentage of proliferation of inhibitortreated cells to control (anti-IgG1 isotype, 10μg/mL, R&D or medium plus vehicle).
DLBCL patients were classified into groups: without (Gr.1) or with (Gr.2) suppressive monocytes. The classification was based on suppressive assay or a number of M-MDSCs at more than 3 fold the median count.
Statistical analysis
Statistical analyses were performed with GraphPad Prism 5.0 software (GraphPad Figure 1A ).
To further identify the immune response pathways affected in DLBCL, these PS were Figure 1B) . Then, by GSEA, we found in our DLBCL cohort a significant enrichment for a list of myeloid genes known to be upregulated in MDSCs (p=0.03) (Supplemental Table 1 and Figure 1C ). Finally, using the same list of myeloid genes (Supplemental Table 1 ), we performed a hierarchical clustering analysis on the 76 DLBCL samples (Supplemental Figure 1) . A group of patients (Group B) with low expressions of MDSC-related genes (including ARG1, S100A12, S100A8, MMP8, SLPI, MPO, CD274, TNFAIP6, CxCL5 and AIM2) showed a better EFS probability than the other group of patients (Group A) (p=0.013) ( Figure 1D ).
Altogether these results were in favor of a myeloid regulatory signature in DLBCL with a clinical impact on patients' prognosis. Figure 2B ).
As described in solid tumors 22 and multiple myeloma, 25 Figure 2D ).
G-MDSCs did not correlate with risk factors or EFS (data not shown). As the myeloid regulatory compartment in peripheral blood also includes dendritic cells, we assessed the 3 subsets of dendritic cells as follows: Lin neg HLA-DR pos CD123 pos CD141 neg CD1c neg pDC, Lin neg HLA-DR pos CD123 neg CD141 pos CD1c neg type 1 cDC, and Lin neg HLA-DR pos CD123 neg CD141 neg CD1c pos type 2 cDC. 35 These cell types were significantly decreased in DLBCL when compared to HD, without correlation with any type of MDSCs (Supplemental Figure 3 ).
M-MDSCs from DLBCL patients suppress T-cell response
MDSC immunosuppressive activities lead to a T-cell proliferation blockade or apoptosis. Noteworthy T-cell count and the ratio of CD3ζ (CD247) to CD3γ mRNA were decreased in DLBCL (p=0.01 and p=0.0009, respectively) ( Figure 3A) . Given the fact that i) in DLBCL, only M-MDSCs were correlated with prognostic, and ii) this subset has been described being the dominant suppressive population of MDSCs, 24 we evaluated the suppressive capability of the monocyte fraction. We noticed that CD8 pos T lymphocytes issued from DLBCL patients proliferated less than those from HD in response to polyclonal activation (p=0.01) ( Figure 3B ). Interestingly, when CD14 pos monocytes were depleted from PBMC, the proliferation index (PI) ratio (monocyte-depleted PBMC to PBMC) was increased for DLBCL patients whereas it was decreased for HD demonstrating a specific suppressive activity for monocytes in lymphoma patients ( Figure 3B ). To evidence the specific in vitro suppressive capacity Figure 3C ). Then, by QPCR analysis performed on 3 DLBCL patients, we found a panel of genes involved in MDSC functions to be slightly increased in CD14 pos HLA-DR low compared to CD14 pos HLA-DR high ( Figure 3D ).
In DLBCL, M-MDSC suppressive activity is independent from arginase I and IDO activities
In B-cell malignancies, arginase 1 and IDO activities were reported in DLBCL 29 and CLL, 27 respectively. MDSCs mediate T-cell suppression through various mechanisms. 21 Therefore, we compared in DLBCL versus HD peripheral blood, the gene expression of 5 key enzymes (ARG1, IDO1, NOS2, HO-1 and PTGS2) involved in MDSC biology. Among those, only ARG1 was significantly increased in DLBCL (p=0.003). IDO1 although not significant, showed a trend of upregulation (1.8 fold) in DLBCL ( Figure 4A ). To evaluate arginase 1 and IDO activities, we measured the concentration of arginine and tryptophan as well as their degradation products, ornithine and kynurenine, respectively. Arginase 1 and IDO activities were increased in DLBCL (p=0.02 and p=0.04, respectively) ( Figure 4B ). Finally, we measured by ELISA the arginase 1 enzyme in plasma and found increased levels in DLBCL samples compared to HD (median at 157.4 vs 16.66 ng/mL, p<0.0001) ( Figure 4C ).
Then, based on the presence or absence of suppressive monocytes, 2 groups of DLBCL were constituted and we showed that in DLBCL the proliferation of CD4 pos and CD8 pos cells issued from PBMC was not increased in the presence of arginase or IDO inhibitors regardless of the presence of M-MDSCs ( Figure 4D ). Interestingly, For personal use only. on July 8, 2016. by guest www.bloodjournal.org From Ǧ ͳ arginase 1 in plasma did not correlate with M-MDSCs, but instead was correlated with the number of immature granulocytes, which contains G-MDSCs 36 (r=0.33, p=0.049) ( Figure 4E ).
IL-10, PDL-1 and S100A12 are involved in M-MDSC suppressive activity
Because of the lack of correlation between M-MDSCs and arginase 1 or IDO in DLBCL, we sought for additional mechanisms of immunosuppression already described for MDSCs, including T reg induction, IL-10 and TGFβ release as well as PD-L1 expression. 21 First, we found that T reg and M-MDSC counts were correlated in DLBCL patients (r=0.5, p=0.039) ( Figure 5A ). We then compared in DLBCL and HD peripheral blood, the gene expression of immunosuppressive molecules. IL10, S100A9 and S100A12 were significantly overexpressed in DLBCL unlike TGFB1 and S100A8. In addition, although not significant, CD274/PD-L1 was also increased in DLBCL by 1.85 fold ( Figure 5B ). Interestingly, although the expression of PD-L1 on M-MDSC was increased in DLBCL (p=0.015) ( Figure 5C ), CD274 expression did not correlate with the circulating malignant B-cell count (data not shown). Similarly, IL-10 was increased at the protein level in DLBCL peripheral blood (p<0.001), and a trend was also noticed for S100A12 (p=0.052) unlike TGF-β1 and S100A8/A9 ( Figure 5D ).
We thus evaluated the levels of IL-10 and S100A12 in culture supernatants from stimulated PBMC, depleted or not from CD14 pos cells. These molecules were decreased after CD14 pos depletion (p<0.05) ( Figure 5E ). Finally, on the 2 groups of DLBCL classified depending on M-MDSC content, we analyzed the percentage of proliferating T cells after CD3/CD28 stimulation in the presence of various blocking antibodies (IL-10, PD-1 and S100A12) ( Figure 6 ). In the group of patients with
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Discussion
Circulating MDSCs have been described in various solid tumors with, in most cases, a predominance of G-MDSCs. 22, 23 Regarding lymphoid neoplasias, both G-and M-MDSCs are increased in Hodgkin lymphoma and in multiple myeloma. 25, 37, 38 Few studies were conducted on B-cell lymphomas or CLL which focused exclusively on the M-MDSC subtype. [27] [28] [29] 39 Since the majority of blood biomarkers in DLBCL are linked to tumor microenvironment and in particular to myeloid cell biology, 6, 7, [14] [15] [16] [17] further characterization of the MDSC compartment is highly relevant in this disease.
Our aim, in this study, was to characterize the various MDSC subsets in peripheral blood from DLBCL patients.
As previously described we found an increase in neutrophil and monocyte counts, whereas the number of lymphocytes was reduced. This was also reflected in (CD14 pos CD163 pos ). 40, 41 We retained the phenotype used in Figure 2 and
Supplemental Figure 2 being the most informative (data not shown), in particular we found CD123 helpful in discarding polynuclear basophils during the gating strategy For personal use only. on July 8, 2016. by guest www.bloodjournal.org From Ǧ ͳ ͻ as their phenotype overlaps G-MDSCs. We then found higher counts of G-MDSCs (Lin neg CD123 low HLA-DR neg CD33 pos CD11b pos ). During the preparation of this manuscript and in agreement with our results, an expansion of myeloid cells with a G-MDSC phenotype has been reported in a small cohort of DLBCL patients (n=5). 42 In our study, G-MDSCs did not correlate with clinical outcomes, nor T reg count.
Additionally, the suppressive fraction of granulocyte was recently identified as remaining granulocytes in the PBMC fraction after density cell separation and called low density neutrophils. 43 In DLBCL, G-MDSCs were detected only in whole blood but were absent from PBMC (data not shown). Thus, we focused our attention to M-
MDSCs.
M-MDSCs (CD14 pos HLA-DR low ) were expanded in DLBCL patients, in concordance with 2 other studies with altogether 41 DLBCL patients. 28, 29 Finally, an additional monocyte subset (CD14 pos CD16 pos ) was found increased in DLBCL although partially overlapping with the M-MDSCs (data not shown). Whether, this latter subset displays suppressive function is controversial. For some authors, these cells do produce the anti-proliferative cytokine IL-10 or induce T reg, 44-46 whereas for others, they highly express HLA-DR and release the pro-inflammatory cytokine TNFα. 47 mice, as the most immunosuppressive subset. 24 In DLBCL, we have shown that CD14 pos cells exerted a suppressive activity on T cells which function and therefore proliferative activity can be restored after having depleted the CD14 pos cells.
In lymphoid malignancies, arginase 1 and IDO are 2 mechanisms of suppression already described. 27, 29 In our study neither arginase 1, nor IDO activity were involved in the MDSC suppressive activity. The arginase 1 protein level was found highly expressed in the plasma without any relationship to M-MDSC subsets but rather correlated to the immature granulocyte fraction. Consequently, arginase 1 might likely be released by granulocytes but is not responsible for the M-MDSC suppressive activity. Two previous papers already reported an expansion of M-MDSCs in DLBCL. One paper did not demonstrate functionally the suppressive activity of these cells, which is essential for the MDSC characterization. 28 The second one did not focus on the DLBCL but rather involved a large variety of non-Hodgkin's lymphomas. Moreover, the functional assays were limited and excepted arginase 1 no other mechanisms of T-cell suppression were explored. 29 These results prompted us to seek for additional suppressive mechanisms in MDSCs from DLBCL. Release of IL-10, TGF-β and activation of the PD-L1/PD-1 axis are known MDSC mechanisms of suppression. [48] [49] [50] [51] Interestingly, in DLBCL we and others have shown that IL-10 and sPD-L1 can be elevated compared to HD. 6, 52 Herein, we demonstrated that monocyte suppressive activity was mediated by a release of IL-10 by CD14 pos cells and an expression of PD-L1 on monocytes. These suppressive activities were impaired by neutralizing antibodies. 53 Nevertheless, in most DLBCL we found beside G-and M-MDSC, an increase of neutrophils, immature granulocytes and monocytes potentially including suppressive subsets, thus we cannot rule out that the mechanisms described in our study could be shared between
For personal use only. on July 8, 2016. by guest www.bloodjournal.org From Ǧ ʹ ͳ various subsets. We also demonstrated that S100A12 is responsible for T-cell suppression in DLBCL. In accordance with this finding, S100A8, S100A9 and S100A12 are expressed in MDSCs from hepatocellular and colorectal carcinomas, 54, 55 and S100 proteins, among other abilities, enhance the suppressive activity of MDSCs via an increase in ROS production. [56] [57] [58] The Here, we demonstrated that in DLBCL at diagnosis, M-MDSCs are predominant and are correlated with a worse prognosis. It would be interesting to monitor these populations during the course of the treatment, indeed accumulation or depletion of MDSCs is influenced by chemotherapy and/or immunotherapy. 59 Our study also point out the potential interest of MDSCs as targets in future therapeutic trials on DLBCL patients. Controlling the expansion and accumulation of MDSCs or blocking their suppressive functions for instance by CSF-R1 60 or S100 family member 61 targeting represents promising novel approaches in cancer therapy. For personal use only. on July 8, 2016. by guest www.bloodjournal.org From Ǧ ͵ Ͳ 
